<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002781</url>
  </required_header>
  <id_info>
    <org_study_id>0452-09</org_study_id>
    <nct_id>NCT01002781</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tocilizumab in Adult's Still Disease</brief_title>
  <official_title>Efficacy and Safety of Tocilizumab (a Monoclonal Antibody to Receptor of IL-6) in the Treatment of Adult's Still Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with adult's Still disease suffer from acute inflammatory symptoms such as fever,
      arthritis, rash, and acute phase response often requiring high dose corticosteroids. In view
      of several case reports which have shown dramatic improvement in patients treated with
      Tocilizumab and a phase 2 study of this drug in children with Still's disease, the objective
      of the current study is to assess the efficacy and safety of Tocilizumab in patients with
      adult's Still disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open, study designed to investigate the effect of Tocilizumab, a
      monoclonal antibody to IL-6 receptor, on the management of active adult-onset Still's
      disease.

      Standard medication of corticosteroid will be given to all patients at the discretion of the
      treating physician.

      Visits will include : screening visit, week o, week 2 , and every 4 weeks after during 52
      weeks After complying with the inclusion and exclusion criteria, patients will start
      treatment with Tocilizumab at a dosage of 8 mg/kg, every 2 weeks Patients will be assessed
      every visit for the presence of fever, tender and swollen joint, rash, dosage of
      corticosteroids and other DMARD's, CRP and ESR
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptom-free or steroid-free remission at 52 weeks</measure>
    <time_frame>52 WEEKS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fever, ACR20, inflammatory markers (e.g. CRP, ferritin), need for rescue medication (e.g. methotrexate, anti-TNF alpha) , adverse events</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Adult's Still Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab, IV, 8 mg/kg, every 2 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have been diagnosed with adult-onset Still's disease according to the
             criteria of Yamaguchi (at least 5 criteria in total, including at least 2 major
             criteria), although these criteria do not have to be present at the time of inclusion
             in the study.

        Major criteria are:Fever ≥39°C for at least 1 week,Arthralgia lasting at least 2
        weeks,Maculo-papular, non-pruritic skin rash,Leucocytosis .≥10,000/mm³) including ≥80%
        neutrophils;Minor criteria are:Pharyngitis or sore throat,Lymphadenopathy or
        splenomegaly,Liver enzyme (transaminase) abnormalities,Negative for rheumatoid factor or
        antinuclear antibodies

          -  Patients aged &gt;18

          -  Capable of signing informed consent

        Exclusion Criteria:

          -  active infections (especially sepsis and Epstein-Barr virus),

          -  malignant disease (especially lymphomas),

          -  other autoimmune or inflammatory disease (especially polyarteritis nodosa)

          -  patients will be required to restrict other treatments for Still's disease to low-dose
             corticosteroids +/- non steroidal anti inflammatory drugs for at least the first 4
             weeks of the study.

          -  pregnant or breast-feeding women

          -  women of childbearing potential unwilling to use adequate contraception and not become
             pregnant during the course of the study

          -  previous treatment with other biologic antirheumatic agents will require a washout
             period before inclusion

          -  history of listeriosis or latent or active tuberculosis

          -  persistent chronic or active recurring infection requiring treatment with antibiotics,
             antivirals, or antifungals within 4 weeks prior to the screening visit, or history of
             frequent recurrent infections unacceptable per investigator judgment.

          -  received administration of any live (attenuated) vaccine within 3 months prior to the
             inclusion visit

          -  known history of Human Immunodeficiency Virus antibody; and/or positive Hepatitis B
             surface antigen , and/or positive Hepatitis C antibody at the screening visit.

          -  history of recurrent herpes zoster.

          -  history of prior articular or prosthetic joint infection

          -  history of a hypersensitivity reaction, other than localised injection site reaction ,
             to any biological molecule

          -  uncontrolled diabetes

          -  patients under dialysis

          -  presence of any of the following laboratory abnormalities at the screening visit:
             haemoglobin &lt;8.5g/l, WBC &lt;3000/μL, platelet count &lt;150,000/μL, neutrophils &lt;1500/μL

          -  AST or ALT &gt;2 Upper limit and bilirubin &gt;2 Upper limit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ori Elkayam, M.D</last_name>
    <phone>97236973668</phone>
    <email>orie@tasmc.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayelet Brill, M.D</last_name>
    <phone>972524266894</phone>
    <email>ayeletb@tasmc.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bnei Tsion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Itzhak Rosner, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Balbir-Gurman, M.D</last_name>
      <phone>972502061162</phone>
      <email>a_balbir@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ori Elkayam, M.D</last_name>
      <phone>97236973668</phone>
      <email>orie@tasmc.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Ayelet Brill</last_name>
      <phone>972524266893</phone>
      <email>ayeletb@tasmc.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Dan Caspi, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daphna Paran, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hagit Savargil-Maman, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Tsrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moshe Tishler, M.D</last_name>
      <phone>972522502909</phone>
      <email>MosheT@asaf.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7.</citation>
    <PMID>18358927</PMID>
  </reference>
  <reference>
    <citation>De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis. 2009 Jan;68(1):153-4. doi: 10.1136/ard.2008.088179.</citation>
    <PMID>19088261</PMID>
  </reference>
  <reference>
    <citation>Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002 Dec;46(12):3388-9.</citation>
    <PMID>12483747</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>October 26, 2009</last_update_submitted>
  <last_update_submitted_qc>October 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ori Elkayam</name_title>
    <organization>Israeli Society of Rheumatology</organization>
  </responsible_party>
  <keyword>Tocilizumab Still</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Still's Disease, Adult-Onset</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

